Navigation Links
Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo

ater than or equal to 5 percent and twice the placebo rate) were gastrointestinal in nature, including nausea, vomiting, constipation and abdominal discomfort.

"These analyses of Phase 2 and Phase 3 studies point out the favorable weight and metabolic profile of patients who received bifeprunox," says Earl Sands, M.D., Vice President, Research and Development at Solvay Pharmaceuticals, Inc. "Patients with schizophrenia have a high risk of developing metabolic side effects, including obesity and high cholesterol."

Philip Ninan, M.D., Vice President, Neuroscience at Wyeth Pharmaceuticals, says, "Through our partnership, Wyeth Pharmaceuticals and Solvay Pharmaceuticals are committed to developing investigational medications for mental health conditions. There is a significant need to expand treatment options and to offer individualized therapy for patients with schizophrenia."

In October 2006, Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. announced that a New Drug Application was submitted to the U.S. Food and Drug Administration for bifeprunox, an investigational antipsychotic for the treatment of schizophrenia and for maintenance of stability. Under the terms of a collaboration agreement entered into in March 2004, Wyeth Pharmaceuticals and Solvay Pharmaceuticals agreed to co-develop and co-commercialize bifeprunox and two other compounds, which are in earlier stages of development, as potential treatments for schizophrenia and other psychiatric conditions. The original compound was discovered by Solvay Pharmaceuticals and is being developed by Wyeth, Solvay Pharmaceuticals and Lundbeck.

Under a new agreement that was announced in January 2007, Wyeth Pharmaceuticals and Solvay Pharmaceuticals will collaborate in a joint discovery effort targeting the identification of small molecules as potential antipsychotic medications. Any compounds discovered as part of the research collaboration will be jointly co-owned and co-patented by Wy
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Managing Preanalytical Processes for Patient Safety
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
6. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
7. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
10. Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
11. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care

Post Your Comments:
(Date:11/6/2009).... 6 SCOLR Pharma, Inc. (...the three and nine months ended September 30, 2009...ent and CEO, said, "We continue to advance discuss...rmulation. Several potential partners have committ...ternal resources as they evaluate the potential co...
(Date:11/6/2009)...PRNewswire/ -- Trius Therapeutics, Inc. announced ...n Form S-1 with the U.S. Securities and Exchange C...lic offering of shares of its common stock. All sh...g will be offered by the Company. ,, Credit Sui...nning manager, Piper Jaffray & Co. is acting a...
(Date:11/6/2009)...Newswire-FirstCall/ -- Caraco Pharmaceutical Labor...rolac tromethamine ophthalmic solution, 0.5% follo...ministration (FDA) for Sun Pharma,s Abbreviated Ne... ophthalmic solution on the first day following pa...rapeutically equivalent to Acular® Ophthalmic...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Siblings target of intervention program 50533 1Both good bad movie characters who smoke influence teens to do the same 50531 1Both good bad movie characters who smoke influence teens to do the same 50531 2Colorectal cancer 9090 1
(Date:11/8/2009)...the battle is won," said Dr. Charmaine Yoest. ,...n a vote of 240-194, the Stupak-Ellsworth-Pitts-Ka...it abortion mandates and funding in HR 3962 passed...fe Action President and CEO Dr. Charmaine Yoest sa...r the pro-life Americans across this country who h...
(Date:11/8/2009)...H.R. 3961 to Secure the Stability of Medicare ,...ement Attributable to: J. James Rohack, M.D., Pres... http://www.newscom.com/cgi-bin/prnh/20081209/AMA...ouse health reform bill, which will help improve t...alls for swift passage of H.R. 3961 to secure the ...
(Date:11/8/2009)...of Health Care Reform Bill ,, Critical legisl...for all Americans ,, BALTIMORE, Nov. 7 /PRNews...States House of Representatives passed critical he... Medicare for seniors and end discrimination by in...s out of affordable health coverage. ,, The Aff...
(Date:11/7/2009)...-USNewswire/ -- The American Medical Association (...r Citizenship and Community Service to Manus C. Kr...e award recognizes physicians who have gone above ... an outstanding public service contribution to the...oday during the opening session of the 2009 Interi...
(Date:11/7/2009)...USNewswire/ -- Members of the AMA are trying a las...on rescinding the AMA,s support of HR 3962. ,,...nsible to their PATIENTS, not the leadership of th...r the Association of American Physicians and Surge...medical groups. ,, "If the AMA leadership igno...
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2
...Dec. 17 OmniComm Systems,Inc. (OTC: OMCM.OB), a l...solutions for clinical trials, today announced tha... financing. OmniComm will use the capital to fina...ers of the Company,s executive,management team inc...
...leader selects software formultistage inventorypla...17 SmartOps Corporation, the leading provider of ...ns, announced that its Enterprise Inventory Optimi... companies optimize their use of working capital w...
...Microencapsulation isn,t a new technology, but it,...nclude the scratch-and-sniff perfume ads in magazi...rhaps mostly for an older generation) carbonless c...roencapsulation technology in a novel self-warming...
...ns of bacteria make their home in the vertebrate g...duties for their host, othersthe pathogensare unwe...typhimurium is one such pathogenic bacterium. It ...for most cases of food-borne illness. Yixin Shi, a...
... and low-cost method of preventing lung disease a...ng practiced widely enough in South-East Asian hos...nvolving the University of Adelaide, Australia. , ... the practice of using antenatal corticosteroids p...
...his week marks the launch of Health,Sciences Onlin...e can search,for and find more than 50,000 courses...d, high-quality, current, cost-free, and ad-free h...ners and public health providers,enabling their tr...
Other Medicine News:Health News:OmniComm Systems, Inc. Raises $5.1 Million in Convertible Debt Financing 2Health News:OmniComm Systems, Inc. Raises $5.1 Million in Convertible Debt Financing 3Health News:SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth Pharmaceuticals 2Health News:Sandia's microencapsulation project gives local entrepreneur warm glow 2Health News:Sandia's microencapsulation project gives local entrepreneur warm glow 3Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 2Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 3Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 4Health News:More can be done to prevent lung disease in Southeast-Asian babies 2Health News:Visionary Undertaking for Global E-Health Education 2Health News:Visionary Undertaking for Global E-Health Education 3Health News:Visionary Undertaking for Global E-Health Education 4
Plus Cylinders only Trial Lens Set
Magnetic LAnthony 15 desaturated Kit (4 lbs)
Opti-Free Express No Rub
Grafton Trial Frame
Medicine Products: